TY - JOUR
T1 - Autoimmune Skin Conditions
T2 - Psoriasis
AU - Clebak, Karl T.
AU - Helm, Leesha A.
AU - Foulke, Galen
AU - Helm, Matthew
N1 - Publisher Copyright:
Written permission from the American Academy of Family Physicians is required for reproduction of this material in whole or in part in any form or medium.
PY - 2023/3/1
Y1 - 2023/3/1
N2 - Psoriasis is a chronic, inflammatory skin condition with significant effect on quality of life. It affects 3.2% of the United States population. Psoriasis is caused by an interaction between genetic and environmental triggers. Associated conditions include depression, increased cardiovascular risk, hypertension, hyperlipidemia, diabetes, nonalcoholic fatty liver disease, Crohn disease, ulcerative colitis, celiac disease, nonmelanoma skin cancers, and lymphoma. Several clinical variants exist, including chronic plaque, guttate, pustular, inverse, and erythrodermic psoriasis. Lifestyle modification and topical therapies, such as emollients, coal tar, topical corticosteroids, vitamin D analogues, and calcineurin inhibitors, are used for limited disease. More severe psoriasis may require systemic therapy with oral or biologic therapy. Individualized management of psoriasis may involve different combinations of treatments. Counseling patients about associated comorbidities is essential.
AB - Psoriasis is a chronic, inflammatory skin condition with significant effect on quality of life. It affects 3.2% of the United States population. Psoriasis is caused by an interaction between genetic and environmental triggers. Associated conditions include depression, increased cardiovascular risk, hypertension, hyperlipidemia, diabetes, nonalcoholic fatty liver disease, Crohn disease, ulcerative colitis, celiac disease, nonmelanoma skin cancers, and lymphoma. Several clinical variants exist, including chronic plaque, guttate, pustular, inverse, and erythrodermic psoriasis. Lifestyle modification and topical therapies, such as emollients, coal tar, topical corticosteroids, vitamin D analogues, and calcineurin inhibitors, are used for limited disease. More severe psoriasis may require systemic therapy with oral or biologic therapy. Individualized management of psoriasis may involve different combinations of treatments. Counseling patients about associated comorbidities is essential.
UR - http://www.scopus.com/inward/record.url?scp=85150135941&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150135941&partnerID=8YFLogxK
M3 - Article
C2 - 36913657
AN - SCOPUS:85150135941
SN - 2159-3000
VL - 526
SP - 7
EP - 12
JO - FP essentials
JF - FP essentials
ER -
